Selected research
Industry Research
Medical Device Viral Inactivation Testing Industry Research Report 2026
Market perspective
The global Medical Device Viral Inactivation Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Medical Device Viral Inactivation Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Medical Device Viral Inactivation Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Medical Device Viral Inactivation Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Medical Device Viral Inactivation Testing include Charles River, Perfectus Biomed (NAMSA), Eurofins Scientific, Nelson Labs, Texcell, Intertek Group, LabCorp, Syensqo and SGS, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Medical Device Viral Inactivation Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Medical Device Viral Inactivation Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medical Device Viral Inactivation Testing Market by Company
Charles River
Perfectus Biomed (NAMSA)
Eurofins Scientific
Nelson Labs
Texcell
Intertek Group
LabCorp
Syensqo
SGS
Pacific BioLabs
Creative Biogene
ProPharma Group
Cormica Lab (Wickham Micro)
CTI
WuXi AppTec
Medical Device Viral Inactivation Testing Segment by Type
DNA-based
RNA-based
Medical Device Viral Inactivation Testing Segment by Application
Active Implant Medical Devices
Active Medical Equipment
In Vitro Diagnostic Equipment
Ophthalmic Medical Equipment
Vascular Medical Equipment
Other
Medical Device Viral Inactivation Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Device Viral Inactivation Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medical Device Viral Inactivation Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Device Viral Inactivation Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Medical Device Viral Inactivation Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DNA-based
- RNA-based
Applications
- Active Implant Medical Devices
- Active Medical Equipment
- In Vitro Diagnostic Equipment
- Ophthalmic Medical Equipment
- Vascular Medical Equipment
- Other
Companies covered
- Charles River
- Perfectus Biomed (NAMSA)
- Eurofins Scientific
- Nelson Labs
- Texcell
- Intertek Group
- LabCorp
- Syensqo
- SGS
- Pacific BioLabs
- Creative Biogene
- ProPharma Group
- Cormica Lab (Wickham Micro)
- CTI
- WuXi AppTec
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Medical Device Viral Inactivation Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 DNA-based
- 2.2.3 RNA-based
- 2.3 Medical Device Viral Inactivation Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Active Implant Medical Devices
- 2.3.3 Active Medical Equipment
- 2.3.4 In Vitro Diagnostic Equipment
- 2.3.5 Ophthalmic Medical Equipment
- 2.3.6 Vascular Medical Equipment
- 2.3.7 Other
- 2.4 Assumptions and Limitations
3 Medical Device Viral Inactivation Testing Breakdown Data by Type
- 3.1 Global Medical Device Viral Inactivation Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Medical Device Viral Inactivation Testing Forecasted Market Size by Type (2027-2032)
4 Medical Device Viral Inactivation Testing Breakdown Data by Application
- 4.1 Global Medical Device Viral Inactivation Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Medical Device Viral Inactivation Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Medical Device Viral Inactivation Testing Market Perspective (2021-2032)
- 5.2 Global Medical Device Viral Inactivation Testing Growth Trends by Region
- 5.2.1 Global Medical Device Viral Inactivation Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Medical Device Viral Inactivation Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Medical Device Viral Inactivation Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Medical Device Viral Inactivation Testing Market Dynamics
- 5.3.1 Medical Device Viral Inactivation Testing Industry Trends
- 5.3.2 Medical Device Viral Inactivation Testing Market Drivers
- 5.3.3 Medical Device Viral Inactivation Testing Market Challenges
- 5.3.4 Medical Device Viral Inactivation Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Medical Device Viral Inactivation Testing Players by Revenue
- 6.1.1 Global Top Medical Device Viral Inactivation Testing Players by Revenue (2021-2026)
- 6.1.2 Global Medical Device Viral Inactivation Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Medical Device Viral Inactivation Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Medical Device Viral Inactivation Testing Head Office and Area Served
- 6.4 Global Medical Device Viral Inactivation Testing Players, Product Type & Application
- 6.5 Global Medical Device Viral Inactivation Testing Manufacturers Established Date
- 6.6 Global Medical Device Viral Inactivation Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Medical Device Viral Inactivation Testing Market Size (2021-2032)
- 7.2 North America Medical Device Viral Inactivation Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Medical Device Viral Inactivation Testing Market Size by Country (2021-2026)
- 7.4 North America Medical Device Viral Inactivation Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Medical Device Viral Inactivation Testing Market Size (2021-2032)
- 8.2 Europe Medical Device Viral Inactivation Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Medical Device Viral Inactivation Testing Market Size by Country (2021-2026)
- 8.4 Europe Medical Device Viral Inactivation Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Medical Device Viral Inactivation Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Medical Device Viral Inactivation Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Medical Device Viral Inactivation Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Medical Device Viral Inactivation Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Medical Device Viral Inactivation Testing Market Size (2021-2032)
- 10.2 South America Medical Device Viral Inactivation Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Medical Device Viral Inactivation Testing Market Size by Country (2021-2026)
- 10.4 South America Medical Device Viral Inactivation Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Medical Device Viral Inactivation Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Medical Device Viral Inactivation Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Medical Device Viral Inactivation Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Medical Device Viral Inactivation Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Charles River
- 12.1.1 Charles River Company Information
- 12.1.2 Charles River Business Overview
- 12.1.3 Charles River Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.1.4 Charles River Medical Device Viral Inactivation Testing Product Portfolio
- 12.1.5 Charles River Recent Developments
- 12.2 Perfectus Biomed (NAMSA)
- 12.2.1 Perfectus Biomed (NAMSA) Company Information
- 12.2.2 Perfectus Biomed (NAMSA) Business Overview
- 12.2.3 Perfectus Biomed (NAMSA) Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.2.4 Perfectus Biomed (NAMSA) Medical Device Viral Inactivation Testing Product Portfolio
- 12.2.5 Perfectus Biomed (NAMSA) Recent Developments
- 12.3 Eurofins Scientific
- 12.3.1 Eurofins Scientific Company Information
- 12.3.2 Eurofins Scientific Business Overview
- 12.3.3 Eurofins Scientific Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.3.4 Eurofins Scientific Medical Device Viral Inactivation Testing Product Portfolio
- 12.3.5 Eurofins Scientific Recent Developments
- 12.4 Nelson Labs
- 12.4.1 Nelson Labs Company Information
- 12.4.2 Nelson Labs Business Overview
- 12.4.3 Nelson Labs Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.4.4 Nelson Labs Medical Device Viral Inactivation Testing Product Portfolio
- 12.4.5 Nelson Labs Recent Developments
- 12.5 Texcell
- 12.5.1 Texcell Company Information
- 12.5.2 Texcell Business Overview
- 12.5.3 Texcell Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.5.4 Texcell Medical Device Viral Inactivation Testing Product Portfolio
- 12.5.5 Texcell Recent Developments
- 12.6 Intertek Group
- 12.6.1 Intertek Group Company Information
- 12.6.2 Intertek Group Business Overview
- 12.6.3 Intertek Group Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.6.4 Intertek Group Medical Device Viral Inactivation Testing Product Portfolio
- 12.6.5 Intertek Group Recent Developments
- 12.7 LabCorp
- 12.7.1 LabCorp Company Information
- 12.7.2 LabCorp Business Overview
- 12.7.3 LabCorp Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.7.4 LabCorp Medical Device Viral Inactivation Testing Product Portfolio
- 12.7.5 LabCorp Recent Developments
- 12.8 Syensqo
- 12.8.1 Syensqo Company Information
- 12.8.2 Syensqo Business Overview
- 12.8.3 Syensqo Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.8.4 Syensqo Medical Device Viral Inactivation Testing Product Portfolio
- 12.8.5 Syensqo Recent Developments
- 12.9 SGS
- 12.9.1 SGS Company Information
- 12.9.2 SGS Business Overview
- 12.9.3 SGS Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.9.4 SGS Medical Device Viral Inactivation Testing Product Portfolio
- 12.9.5 SGS Recent Developments
- 12.10 Pacific BioLabs
- 12.10.1 Pacific BioLabs Company Information
- 12.10.2 Pacific BioLabs Business Overview
- 12.10.3 Pacific BioLabs Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.10.4 Pacific BioLabs Medical Device Viral Inactivation Testing Product Portfolio
- 12.10.5 Pacific BioLabs Recent Developments
- 12.11 Creative Biogene
- 12.11.1 Creative Biogene Company Information
- 12.11.2 Creative Biogene Business Overview
- 12.11.3 Creative Biogene Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.11.4 Creative Biogene Medical Device Viral Inactivation Testing Product Portfolio
- 12.11.5 Creative Biogene Recent Developments
- 12.12 ProPharma Group
- 12.12.1 ProPharma Group Company Information
- 12.12.2 ProPharma Group Business Overview
- 12.12.3 ProPharma Group Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.12.4 ProPharma Group Medical Device Viral Inactivation Testing Product Portfolio
- 12.12.5 ProPharma Group Recent Developments
- 12.13 Cormica Lab (Wickham Micro)
- 12.13.1 Cormica Lab (Wickham Micro) Company Information
- 12.13.2 Cormica Lab (Wickham Micro) Business Overview
- 12.13.3 Cormica Lab (Wickham Micro) Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.13.4 Cormica Lab (Wickham Micro) Medical Device Viral Inactivation Testing Product Portfolio
- 12.13.5 Cormica Lab (Wickham Micro) Recent Developments
- 12.14 CTI
- 12.14.1 CTI Company Information
- 12.14.2 CTI Business Overview
- 12.14.3 CTI Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.14.4 CTI Medical Device Viral Inactivation Testing Product Portfolio
- 12.14.5 CTI Recent Developments
- 12.15 WuXi AppTec
- 12.15.1 WuXi AppTec Company Information
- 12.15.2 WuXi AppTec Business Overview
- 12.15.3 WuXi AppTec Revenue in Medical Device Viral Inactivation Testing Business (2021-2026)
- 12.15.4 WuXi AppTec Medical Device Viral Inactivation Testing Product Portfolio
- 12.15.5 WuXi AppTec Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst